Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-07-29
2008-07-29
Wehbe, Anne Marie (Department: 1633)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S325000
Reexamination Certificate
active
11189279
ABSTRACT:
The present invention provides isolated nucleic acids encoding delta DNA methyltransferase 3B molecules that are involved in the treatment and prevention of cancers such as, but not limited to, lung cancer. The delta DNA methyltransferase 3B molecules of the present invention are found to play a critical role in promoter-specific methylation of tumor suppressor genes. The DNA methyltransferase 3B molecules of the present invention are provided as therapeutic targets for identifying inhibitors of DNA methyltransferase. Such inhibitors are contemplated for the treatment and/or prevention of cancers. In particular embodiments, the present invention involves the treatment and prevention of a non-small cell lung cancer.
REFERENCES:
patent: 2004/0234997 (2004-11-01), Li et al.
patent: WO9967397 (1999-12-01), None
patent: WO 9967397 (1999-12-01), None
patent: WO02009126 (2002-11-01), None
patent: WO 2004/030615 (2004-04-01), None
Xie et al., Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene vol. 236, Issue 1 , Aug. 5, 1999, pp. 87-95.
Xu et al.,Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene.Nature. Nov. 11, 1999;402(6758):187-91.
Deloukas P et al., The DNA sequence and comparative analysis of human chromosome 20.Nature. Dec. 20-27, 2001;414(6866):865-71 PMID: 11780052 [PubMed—indexed for Medline] (abstract).
Robertson et al., The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors.Nucleic Acids Res. Jun. 1, 1999;27(11):2291-8.
Kang et al., Dnmt3b, de Novo DNA Methyltransferase, Interacts with SUMO-1 and Ubc9 through Its N-Terminal Region and Is Subject to Modification by SUMO-1 Biochemical and Biophysical Research Communications vol. 289, Issue 4 , Dec. 14, 2001, pp. 862-868.
Okano et al., DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development. Cell. Oct. 29, 1999;99(3):247-57.
Hansen et al., The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome.Proc Natl Acad Sci U S A. Dec. 7, 1999;96(25):14412-7.
Wijmenga et al., Genetic variation in ICF syndrome: evidence for genetic heterogeneity.Hum Mutat. Dec. 2000;16(6):509-17. Review.
STIC search tittled “us-11-189-279-18.rup”. pp. 1-3.
SITC search tillted “us-11-189-279-18.rapbm”. pp. 1-2.
SITC search tillted “us-11-189-279-18.rag”. pp. 1-5.
Score Result 3, p. 7-11, on the attached search print out titled us-11-189-279-1.rng pp. 1-16.
Chen et al., Physical and functional interactions between the human DNMT3L protein and members of the de novo methyltransferase family. Journal of Cellular Biochemistryvol. 95, Issue 5, pp. 902-917.
Score. Result 1, p. 1-6, on the attached search print out titled us-11-189-279-4.rge.
National Center for Biotechnology Information, GenBank Accession No. W76111, GenBank database; Jun. 14, 1996.
National Center for Biotechnology Information, GenBank Accession No. N88352, GenBank database; Apr. 2, 1996.
National Center for Biotechnology Information, GenBank Accession No. F12227, GenBank database; Mar. 13, 1995.
National Center for Biotechnology Information, GenBank Accession No. T66356, GenBank database; Feb. 20, 1995.
National Center for Biotechnology Information, GenBank Accession No. AA761775, GenBank database; Jan. 28, 1998.
National Center for Biotechnology Information, GenBank Accession No. G06200, GenBank database; Oct. 19, 1995.
National Center for Biotechnology Information, GenBank Accession No. G15302, GenBank database; Mar. 30, 2000.
National Center for Biotechnology Information, GenBank Accession No. AL035071, GenBank database; May 18, 2005.
National Center for Biotechnology Information, GenBank Accession No. AF135438, GenBank database; Sep. 8, 1999.
Baylin, “Altered methylation patterns in cancer cell genomes: Cause or consequence?”Cancer Cell, 1: 299-305, 2002.
Belinsky et al., “Aberrant methylation ofp16INK4ais an early event in lung cancer and a potential biomarker for early diagnosis,”Proc. Natl. Acad. Sci. USA, 95: 11891-11896, 1998.
Belinsky et al., “Aberrant Promoter Methylation in Bronchial Epithelium and Spatum from Current and Former Smokers,”Cancer Res., 62: 2370-2377, 2002.
Brauch et al., “Molecular Analysis of the Short Arm of Chromosome 3 in Small-Cell and Non-Small-Cell Cancinoma of the Lung,”The New England Journal of Medicine, 317(18): 1109-13, 1987.
Burbee et al., “Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression,”J. Natl. Cancer Inst., 93: 691-9, 2001.
Cedar, “DNA Methylation and Gene Activity,”Cell, 53: 3-4, 1988.
Dammann et al., “Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3,”Nature Genetics, 25: 315-319, 2000.
Leu et al., “Double RNA Interference ofDNMT3bandDNMT1Enhances DNA Demethylation and Gene Reactivation,”Cancer Res., 63: 6110-6115, 2003.
Ortiz-Vega et al., “The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1,”Oncogene, 21: 1381-1390, 2002.
Oue et al., “DNA methylation status ofhMLH1, p16INK4a, andCDH1is not associated with mRNA expression levels of DNA methyltransferase and DNA demethylase in gastric carcinomas,”Oncology Reports, 8: 1085-1089, 2001.
Pfeifer et al., “Methylation of theRASSF1AGene in Human Cancers,”Biol. Chem., 383: 907-914, 2002.
Reik et al., “Epigenetic Reprogramming in Mammalian Development,”Science, 293: 1089-1093, 2001.
Rhee et al., “CpG methylation is maintained in human cancer cells lackingDNMT1,” Nature, 404: 1003-1007, 2000.
Rhee et al., “DNMT1 and DNMT3b cooperate to silence genes in human cancer cells,”Nature, 416: 552-556, 2002.
Robertson et al., “The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors,”Nucleic Acids Research, 27(11): 2291-2298, 1999.
Saito et al., “Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis,”PNAS, 99(15): 10060-10065, 2002.
Shen et al., “A Novel Polymorphism in Human Cytosine DNA-Methyltransferase-3B Promoter Is Associated with an Increased Risk of Lung Cancer,”Cancer Res., 62: 4992-4995, 2002.
Soria et al., “Aberrant Promoter Methylation of Multiple Genes in Bronchial Brush Samples from Former Cigarette Smokers,”Cancer Res., 62: 351-355, 2002.
Wang et al., “A novel C/T polymorphism in the core promoter of humande novocytosine DNA methyltransferase 3B6 is associated with prognosis in head and neck cancer,”International Journal of Oncology, 25: 993-999, 2004.
Weisenberger et al., “Role of the DNA Methyltransferase Variant DNMT3b3 in DNA Methylation,”Molecular Cancer Research, 2: 62-72, 2004.
Yakushiji et al., “Over-expression of DNA methyltransferases and CDKN2A gene methylation status in squamous cell carcinoma of the oral cavity,”International Journal of Oncology, 22: 1201-1207, 2003.
Mao Li
Wang Jie
Wang Luo
Board of Regents , The University of Texas System
Fulbright & Jaworski LLP
Leavitt Maria
Wehbe Anne Marie
LandOfFree
Method of treating a cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating a cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating a cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3957624